Pulmonary Pharmacology & Therapeutics

Papers
(The H4-Index of Pulmonary Pharmacology & Therapeutics is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)40
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics37
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies27
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study27
Echocardiographic effects of dupilumab in patients with severe type 2 asthma23
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation22
Editorial Board20
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function20
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients19
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d18
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens16
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets16
Editorial Board15
Editorial Board15
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential15
0.2405059337616